Cetuximab for the treatment of colorectal cancer.

@article{Jonker2007CetuximabFT,
  title={Cetuximab for the treatment of colorectal cancer.},
  author={Derek J. Jonker and Chris J O'Callaghan and Christos S Karapetis and John R Zalcberg and Dongsheng Tu and H J Au and S. R. Berry and Marianne Krahn and Timothy Jay Price and Robert John Simes and Niall C. Tebbutt and Guy van Hazel and Rafal F Wierzbicki and Christiane Langer and Malcolm J. Moore},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 20},
  pages={2040-8}
}
BACKGROUND Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS